TABLE 3.
SOCE inhibitors in cancer research.
| Compound | Cancer type | Cell lines | Major effect | Possible mechanisms | References |
|---|---|---|---|---|---|
| SKF96365 | MG astrocytoma | U373 | Inhibition of cell growth | Promotes the accumulation of [3H]IP1 and inhibits the mobilization of intracellular Ca2+ | Lee et al. (1993); Arias-Montaño et al. (1998) |
| Cervical cancer | Hela | Inhibition of cell growth and cell migration | Promotes the accumulation of [3H]IP1 | Arias-Montaño et al. (1998); Chen Y.-T. et al. (2013) | |
| SiHa | Inhibits the activation of non-muscle myosin II and the formation of actomyosin via blocking SOCE channel | ||||
| Neuroblastoma | SK-N-MC | Inhibition of cell growth | Inhibits the mobilization of intracellular Ca2+ | Lee et al. (1993) | |
| Gastric cancer | AGS and MKN45 | Inhibition of cell growth and tumor formation | Arrests cell cycle in G2/M phase | Cai et al. (2009) | |
| Nasopharyngeal carcinoma | CNE2 and HONE1 | Inhibition of cell proliferation and colony formation, promotion of apoptosis and cell-cycle | Distracts the transduction of oncogenic Ca2+ signaling | Zhang et al. (2015) | |
| Colorectal cancer | HCT116 and HT29 | Inhibition of cell growth and tumor formation, inducement of apoptosis, cell-cycle and autophagy | Inhibits the calcium/CaMKIIγ/AKT-mediated pathway | Jing et al. (2016) | |
| Prostate cancer | DU145 and PC3 | Inhibition of the survival and proliferation | Inhibits AKT/mTOR pathway and induces autophagy | Selvaraj et al. (2016) | |
| Multiple myeloma | KM3 and U266 | Inhibition of cell viability and proliferation, inducement of apoptosis | Arrests cell cycle in G2/M phase. Induces the reduction of [Ca2+]i | Wang W. et al. (2018) | |
| Ovarian cancer | SKOV3 | Inhibition of cell proliferation | Arrests cell cycle in G2/M phase through inhibiting TRPC channels | Zeng et al. (2013) | |
| Glioma and glioblastoma | U251, U87, D54MG, LN-229, T98G, U373 | Inhibition of cell growth and colony formation. Increase in the sensitivity to irradiation | Inhibits TRPC channels. Arrests cell cycle in G2/M phase | Bomben and Sontheimer (2008); Ding et al. (2010); Song et al. (2014) | |
| Breast tumor | MDA-MB-231 | Inhibition of cell migration, inhibition of tumor Metastasis in mice | Impairs the assembly and disassembly of focal adhesions | Yang et al. (2009) | |
| Melanoma | WM793 | Inhibition of cell invasion | Blocks the formation, activity of invadopodium | Sun et al. (2014) | |
| Non-small cell lung cancer | A549 | Inhibition of cell migration and proliferation | Inhibits TRPC channels and SOCE channel | Wang Y. et al. (2018) | |
| 2-APB | Rhabdomyosarcoma (RMS) | RD, RH30 | Inhibition of cell proliferation, migration and invasion | Inhibits SOCE channel | Schmid et al. (2016) |
| Melanoma | WM793 | Inhibition of cell invasion and lung metastasis | Blocks the formation, activity and maturation of invadopodium | Sun et al. (2014) | |
| Cervical cancer | SiHa | Inhibition of cell migration | Inhibits actomyosin formation and cellular contractile force via blocking SOCE channel | Chen Y.-T. et al. (2013) | |
| Ovarian cancer | SKOV3 | Inhibition of cell proliferation | Inhibits TRPC channels | Zeng et al. (2013) | |
| Breast cancer | MDA-MB-231, AU565, T47D | Inhibition of cell viability and proliferation | Arrests cell cycle in S phase | Liu et al. (2020) | |
| Prostate cancer | DU145, PC3 | Inhibition of cell migration | Inhibits EMT via blocking TRPM7 channel activity | Sun et al. (2018) | |
| Glioma and glioblastoma | D54MG, U87 | Inhibition of cell development, migration and invasion | Inhibits SOCE channel and TRPC channels (TRPC1, TRPC3, TRPC5, TRPC6) | Bomben and Sontheimer (2008); Shi et al. (2015) | |
| GBM (Glioblastoma multiforme) | A172 | Inhibition of cell proliferation, migration and invasion | Inhibits TRPM7 channel | Leng et al. (2015) | |
| Nasopharyngeal carcinoma | CNE2, 5-8F, 6-10B | Inhibition of cell migration and invasion | Inhibits TRPC1 and TRPM7 channel | Chen et al. (2010); He et al. (2012) | |
| HK1 | Inhibition of angiogenesis | Inhibits VEGF production and endothelial tube formation by blocking SOCE | Ye et al. (2018) | ||
| Non-small-cell lung cancer (NSCLC) | H1975, A549, LLC-1 | Inhibition of primary and metastatic Lewis lung cancer | Inhibits intracellular Ca2+mobilization | Qu et al. (2018) | |
| BTP2 | Colon cancer | HT29 | Inhibition of cell growth | Inhibits SOCE channel and transcription cycling of topoisomerase-II α | Núñez et al. (2006) |
| Cervical cancer | SiHa | Inhibition of cell migration | Inhibits actomyosin formation and cellular contractile force via blocking SOCE channel | Chen Y.-T. et al. (2013) | |
| Rhabdomyosarcoma (RMS) | RD, RH30 | Inhibition of cell proliferation, migration and invasion | Inhibits SOCE channel | Schmid et al. (2016) | |
| Breast cancer | MDA-MB-468 | Inhibition of cell proliferation, migration and invasion | Inhibits SOCE channel | Azimi et al. (2018) | |
| Prostate cancer | PC-3 | Inhibition of cell invasion | Inhibits drebrin to bind to actin filaments | Dart et al. (2017) | |
| Pyr3 | triple negative breast cancer | MDA-MB-231 | Inhibition of cell proliferation, inducement of apoptosis and cell death | Affects the TRPC3/RASA4/MAPK Pathway | Wang et al. (2019) |
| Melanoma | C8161 | Inhibition of cell proliferation and migration | Inhibits TRPC3 channel | Oda et al. (2017) | |
| Glioblastoma multiforme | LN229, U87 | Inhibition of cell proliferation, migration and invasion | Dephosphorylates focal adhesion kinase and myosin light chain via inhibiting TRPC3 channel | Chang et al. (2018) | |
| CAI | Melanoma | A2058 | Inhibition of cell proliferation, adhesion and motility | Inhibits the receptor-mediated stimulation of effector enzymes | Kohn and Liotta (1990); Kohn et al. (1992) |
| Inhibition growth and metastasis of transplanted xenografts | Inhibits calcium fluxes, arachidonic acid release, and phosphoinositides generation | ||||
| Breast cancer | MDA-MB-231 | Inhibition of cell proliferation, adhesion and motility | Inhibits the receptor-mediated stimulation of effector enzymes | Kohn and Liotta. (1990) | |
| Ovarian cancer | OVCAR-3 | Inhibition of cell proliferation, adhesion and motility | Inhibits the receptor-mediated stimulation of effector enzymes | Kohn and Liotta (1990); Kohn et al. (1992) | |
| Inhibition growth and metastasis of transplanted xenografts | Inhibits calcium fluxes, arachidonic acid release, and phosphoinositides generation | ||||
| Colon cancer | HT-29 | Inhibition of the formation and growth of experimental pulmonary metastases in nude mice | Inhibits calcium fluxes, arachidonic acid release, and phosphoinositides generation | Kohn et al. (1992) | |
| Prostate cancer | DU-145, PPC-1, PC3, LNCaP | Inhibition of cell proliferation | Inhibits calcium fluxes and PSA production | Wasilenko et al. (1996) | |
| Glioblastoma | A172, T98G, U87, H4, U251 | Inhibition of cell proliferation and adhesion | Inhibits calcium fluxes and calcium-sensitive signal transduction pathways | Jacobs et al. (1997) | |
| Head and neck squamous cell carcinoma | EVSCC14/17M, EVSCC19M, EVSCC18, UMSCC10A, FaDu | Inhibition of cell growth and invasion | Inhibits calcium fluxes | Wu et al. (1997) | |
| Hepatoma | Hep G2, Huh-7 | Inhibition of cell proliferation | Inhibits calcium entry | Enfissi et al. (2004) | |
| Small cell lung cancer | NCI-H209, NCI- H345 | Inhibition of cell growth, inhibition of xenograft proliferation in nude mice | Inhibits calcium fluxes | Moody et al. (2003) | |
| Inhibits the angiogenesis | |||||
| Chronic myeloid leukemia | 32D P210, 32D E255K | Inhibition of cell growth and decrease of BCR-ABL | Inhibits calcium influxes and signal transduction | Corrado et al. (2011) | |
| Liver metastases from B16F1 melanoma | B16F1 | Decrease of the volume size and angiogenesis of tumor | Reduces the number of microvessels/mm2 and microvessel size | Luzzi et al. (1998) | |
| Lewis lung carcinoma | LLC cell | Inhibition of cell growth | Inhibits production of pro-inflammatory cytokines in TAMs | Ju et al. (2012) | |
| Melanoma | OVA-B16 | Inhibition of tumor growth | Activates the CD8+ T cells and stimulates IDO1-Kyn metabolic circuitry | Shi et al. (2019) | |
| RP4010 | Esophageal cancer | KYSE-30, KYSE-150, KYSE-790, KYSE-190 | Inhibition of cell proliferation and tumor growth | Inhibits SOCE channel-mediated Ca2+ oscillations | Cui et al. (2018) |
| Pancreatic ductal adenocarcinoma | L3.6pl, BxPC-3, MiaPaCa-2 | Inhibition of cell proliferation and colony formation | Inhibits CRAC channel | Khan et al. (2020) | |
| ML-9 | Pancreatic cancer | MIA PaCa-2, Panc1, BxPC3 | Inhibition of cell invasion and adhesion | Inhibits MLCK to decrease the activity of cytoskeleton | Kaneko et al. (2002) |
| Prostate cancer | LNCaP, PC3, DU-145 | Inducement of prostate cell death | Stimulates autophagy via modulating Ca2+ homeostasis | Kondratskyi et al. (2014) | |
| NPPB | Ovarian cancer | A2780 | Inhibition of cell adhesion and invasion | Inhibits chloride channels leading to inhibition of [Ca2+]i | Li et al. (2009) |
| YZ129 | Glioblastoma | U87 | Inhibition of cell proliferation, migration and mobility | Inhibits calcineurin-NFAT pathway | Liu et al. (2019) |
| NSAIDs | Colon cancer | HT29 | Inhibition of cell growth | Inhibits SOCE channel and COX-2 expression | Núñez et al. (2006); Wang et al. (2015) |